{"disease":{"id":"fibrosis","name":"fibrosis"},"drugs":{"marketed":[{"drug_id":"elexacaftor","indication_name":"Cystic fibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trikafta (Copackaged)","generic_name":"ELEXACAFTOR","company_name":"Vertex Pharms Inc","drug_phase":"marketed","molecular_target":"Cystic fibrosis transmembrane conductance regulator","drug_class":"","quality_score":65,"revenue":"11100","mechanism":"Trikafta works by correcting the faulty protein that causes cystic fibrosis, allowing the body to produce normal amounts of mucus."},{"drug_id":"ruxolitinib","indication_name":"Myelofibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jakafi","generic_name":"RUXOLITINIB","company_name":"Incyte Corp","drug_phase":"marketed","molecular_target":"Ankyrin repeat and protein kinase domain-containing protein 1, Bone morphogenetic protein receptor type-1B, Calcium/calmodulin-dependent protein kinase type IV","drug_class":"","quality_score":null,"revenue":"2600","mechanism":null},{"drug_id":"nintedanib","indication_name":"Interstitial fibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ofev","generic_name":"NINTEDANIB","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Receptor-type tyrosine-protein kinase FLT3","drug_class":"Kinase Inhibitor","quality_score":70,"revenue":"2000","mechanism":"Ofev works by blocking enzymes that promote fibrosis and tumor growth."},{"drug_id":"nintedanib","indication_name":"Idiopathic pulmonary fibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ofev","generic_name":"NINTEDANIB","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Receptor-type tyrosine-protein kinase FLT3","drug_class":"Kinase Inhibitor","quality_score":70,"revenue":"2000","mechanism":"Ofev works by blocking enzymes that promote fibrosis and tumor growth."},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"acetadote","indication_name":"Cystic fibrosis of the lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Acetadote","company_name":"University of Texas Southwestern Medical Center","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter, Cytochrome c, Glutathione synthetase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"tobramycin","indication_name":"Synergy for P. Aeruginosa Infection in Cystic Fibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tobi","generic_name":"tobramycin","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"fedratinib-hydrochloride","indication_name":"Myelofibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inrebic","generic_name":"FEDRATINIB HYDROCHLORIDE","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"JAK2, FLT3","drug_class":"","quality_score":62,"revenue":null,"mechanism":"Fedratinib inhibits JAK2 and FLT3 kinases, reducing STAT3/5 phosphorylation and cell proliferation in MPNs."},{"drug_id":"fedratinib-hydrochloride","indication_name":"Post-essential thrombocythaemia myelofibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inrebic","generic_name":"FEDRATINIB HYDROCHLORIDE","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"JAK2, FLT3","drug_class":"","quality_score":62,"revenue":null,"mechanism":"Fedratinib inhibits JAK2 and FLT3 kinases, reducing STAT3/5 phosphorylation and cell proliferation in MPNs."},{"drug_id":"fedratinib-hydrochloride","indication_name":"Post-polycythaemia vera myelofibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inrebic","generic_name":"FEDRATINIB HYDROCHLORIDE","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"JAK2, FLT3","drug_class":"","quality_score":62,"revenue":null,"mechanism":"Fedratinib inhibits JAK2 and FLT3 kinases, reducing STAT3/5 phosphorylation and cell proliferation in MPNs."},{"drug_id":"fedratinib-hydrochloride","indication_name":"Primary myelofibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inrebic","generic_name":"FEDRATINIB HYDROCHLORIDE","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"JAK2, FLT3","drug_class":"","quality_score":62,"revenue":null,"mechanism":"Fedratinib inhibits JAK2 and FLT3 kinases, reducing STAT3/5 phosphorylation and cell proliferation in MPNs."},{"drug_id":"colistimethate-sodium","indication_name":"Pseudomonas Respiratory Tract Infection in Cystic Fibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coly-Mycin M","generic_name":"COLISTIMETHATE SODIUM","company_name":"Ph Health","drug_phase":"marketed","molecular_target":"","drug_class":"Polymyxin-class Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tobramycin-sulfate","indication_name":"Synergy for P. Aeruginosa Infection in Cystic Fibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vantobra","generic_name":"Tobramycin Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20","drug_class":"tobramycin","quality_score":68,"revenue":null,"mechanism":""},{"drug_id":"acetylcysteine","indication_name":"Cystic fibrosis of the lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Acetadote","generic_name":"Acetylcysteine","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Glutathione levels; reactive metabolite of acetaminophen","drug_class":"Antidote","quality_score":62,"revenue":null,"mechanism":"Acetylcysteine reduces liver injury from acetaminophen overdose by maintaining glutathione levels or providing alternate conjugation substrate."},{"drug_id":"vitamin-k1","indication_name":"Hypoprothrombinemia secondary to cystic fibrosis of the pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin K1","generic_name":"Phytonadione","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Vitamin K-dependent carboxylase; vitamin K epoxide reductase complex (indirect antagonism of warfarin effects)","drug_class":"Vitamin K [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"nebcin","indication_name":"Synergy for P. Aeruginosa Infection in Cystic Fibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nebcin","company_name":"University Hospital, Lille","drug_phase":"discontinued","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"acetylcystein","indication_name":"Cystic fibrosis of the lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Acetylcystein","company_name":"University Hospital, Strasbourg, France","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter, Cytochrome c, Glutathione synthetase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"mannitol-20","indication_name":"Cystic fibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mannitol","generic_name":"Mannitol","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Glomerular filtrate osmolarity; intracellular water movement","drug_class":"Osmotic diuretic","quality_score":66,"revenue":null,"mechanism":"Osmotic diuretic that elevates glomerular filtrate osmolarity to inhibit tubular water reabsorption."},{"drug_id":"tezacaftor","indication_name":"Cystic fibrosis of the lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Symdeko (Copackaged)","generic_name":"TEZACAFTOR","company_name":"Vertex Pharms","drug_phase":"marketed","molecular_target":"CFTR","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Tezacaftor and ivacaftor work together to increase the amount and function of CFTR protein at the cell surface, enhancing chloride transport."},{"drug_id":"adenosine-phosphate","indication_name":"Cystic fibrosis of the lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Adenovite","generic_name":"ADENOSINE PHOSPHATE","company_name":"","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase Src","drug_class":"Adenosine Receptor Agonist","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"part-c-met097","indication_name":"Treatment of Primary Myelofibrosis (PMF)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(Part C) MET097","generic_name":"part-c-met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":37,"revenue":null,"mechanism":"The exact mechanism of action is not specified on Wikipedia."},{"drug_id":"ofev","indication_name":"Idiopathic pulmonary fibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"OFEV®","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Calcium/calmodulin-dependent protein kinase type IV, Cyclin-dependent kinase 18, Cyclin-dependent kinase-like 2","drug_class":"Kinase Inhibitor","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"ofev","indication_name":"Interstitial fibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"OFEV®","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Calcium/calmodulin-dependent protein kinase type IV, Cyclin-dependent kinase 18, Cyclin-dependent kinase-like 2","drug_class":"Kinase Inhibitor","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"fedratinib","indication_name":"Myelofibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inrebic","generic_name":"FEDRATINIB","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cyclin-G-associated kinase","drug_class":"","quality_score":75,"revenue":null,"mechanism":"Inrebic works by blocking the activity of Cyclin-G-associated kinase, a protein involved in the proliferation and survival of bone marrow cells."},{"drug_id":"fedratinib","indication_name":"Post-essential thrombocythaemia myelofibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inrebic","generic_name":"FEDRATINIB","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cyclin-G-associated kinase","drug_class":"","quality_score":75,"revenue":null,"mechanism":"Inrebic works by blocking the activity of Cyclin-G-associated kinase, a protein involved in the proliferation and survival of bone marrow cells."},{"drug_id":"fedratinib","indication_name":"Post-polycythaemia vera myelofibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inrebic","generic_name":"FEDRATINIB","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cyclin-G-associated kinase","drug_class":"","quality_score":75,"revenue":null,"mechanism":"Inrebic works by blocking the activity of Cyclin-G-associated kinase, a protein involved in the proliferation and survival of bone marrow cells."},{"drug_id":"fedratinib","indication_name":"Primary myelofibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inrebic","generic_name":"FEDRATINIB","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cyclin-G-associated kinase","drug_class":"","quality_score":75,"revenue":null,"mechanism":"Inrebic works by blocking the activity of Cyclin-G-associated kinase, a protein involved in the proliferation and survival of bone marrow cells."},{"drug_id":"l-cysteine","indication_name":"Cystic fibrosis of the lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"L-cysteine","company_name":"Louisiana State University Health Sciences Center Shreveport","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter","drug_class":"Amino acid derivative","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"aztreonam","indication_name":"Respiratory Cystic Fibrosis with Pseudomonas aeruginosa Colonization","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azactam","generic_name":"AZTREONAM","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Monobactam Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Aztreonam inhibits bacterial cell wall synthesis, acting as a bactericidal agent."},{"drug_id":"nerandomilast","indication_name":"Idiopathic Pulmonary Fibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jascayd","generic_name":"NERANDOMILAST","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Jascayd works by inhibiting the activity of phosphodiesterase 4, an enzyme involved in the inflammatory response."},{"drug_id":"nerandomilast","indication_name":"Progressive Pulmonary Fibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jascayd","generic_name":"NERANDOMILAST","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Jascayd works by inhibiting the activity of phosphodiesterase 4, an enzyme involved in the inflammatory response."},{"drug_id":"brensocatib","indication_name":"non-cystic fibrosis bronchiectasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brinsupri","generic_name":"BRENSOCATIB","company_name":"Insmed Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Brinsupri works by inhibiting the activity of a protein that contributes to airway damage and inflammation."},{"drug_id":"brensocatib","indication_name":"non-cystic fibrosis bronchiectasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brinsupri","generic_name":"BRENSOCATIB","company_name":"Insmed Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Brinsupri works by inhibiting the activity of a protein that contributes to airway damage and inflammation."},{"drug_id":"ivacaftor","indication_name":"Cystic fibrosis of the lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kalydeco","generic_name":"IVACAFTOR","company_name":"Vertex Pharms Inc","drug_phase":"marketed","molecular_target":"Cystic fibrosis transmembrane conductance regulator","drug_class":"Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]","quality_score":10,"revenue":null,"mechanism":"Kalydeco works by helping the defective protein in cystic fibrosis cells function more normally."},{"drug_id":"vanzacaftor","indication_name":"cystic fibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alyftrek","generic_name":"VANZACAFTOR","company_name":"Vertex Pharms Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]","quality_score":10,"revenue":null,"mechanism":"Alyftrek potentiates the CFTR protein to facilitate chloride ion flow into cells."},{"drug_id":"tezacaftor","indication_name":"Cystic Fibrosis Treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Symdeko (Copackaged)","generic_name":"TEZACAFTOR","company_name":"Vertex Pharms","drug_phase":"marketed","molecular_target":"CFTR","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Tezacaftor and ivacaftor work together to increase the amount and function of CFTR protein at the cell surface, enhancing chloride transport."},{"drug_id":"mannitol","indication_name":"Cystic fibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aridol Kit","generic_name":"MANNITOL","company_name":"Baxter","drug_phase":"marketed","molecular_target":"sodium channels","drug_class":"Osmotic Diuretic [EPC]","quality_score":75,"revenue":null,"mechanism":"Mannitol works by drawing water into the bloodstream from surrounding tissues, increasing urine production and reducing fluid accumulation in the body."},{"drug_id":"pacritinib","indication_name":"Myelofibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vonjo","generic_name":"PACRITINIB","company_name":"Sobi","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase JAK2","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Vonjo works by blocking the activity of the JAK2 enzyme, which is overactive in myelofibrosis patients."},{"drug_id":"dornase-alfa","indication_name":"Cystic fibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pulmozyme","generic_name":"DORNASE ALFA","company_name":"Roche","drug_phase":"marketed","molecular_target":"","drug_class":"Recombinant Human Deoxyribonuclease 1 [EPC]","quality_score":44,"revenue":null,"mechanism":"Pulmozyme breaks down DNA in the airways to reduce mucus viscosity."},{"drug_id":"cysteine","indication_name":"Cystic fibrosis of the lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cysteine Hydrochloride","generic_name":"CYSTEINE","company_name":"Exela Pharma","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter","drug_class":"Vitamin C [EPC]","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"prednisolone","indication_name":"Fibrosis of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"kalydeco","indication_name":"Cystic fibrosis of the lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Kalydeco","company_name":"Concert Pharmaceuticals","drug_phase":"marketed","molecular_target":"Cystic fibrosis transmembrane conductance regulator","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Fibrosis of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"vargatef","indication_name":"Idiopathic pulmonary fibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"vargatef","company_name":"ARCAGY/ GINECO GROUP","drug_phase":"discontinued","molecular_target":"Calcium/calmodulin-dependent protein kinase type IV, Cyclin-dependent kinase 18, Cyclin-dependent kinase-like 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"vargatef","indication_name":"Interstitial fibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"vargatef","company_name":"ARCAGY/ GINECO GROUP","drug_phase":"discontinued","molecular_target":"Calcium/calmodulin-dependent protein kinase type IV, Cyclin-dependent kinase 18, Cyclin-dependent kinase-like 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"vanzacaftor","indication_name":"cystic fibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alyftrek","generic_name":"VANZACAFTOR","company_name":"Vertex Pharms Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]","quality_score":10,"revenue":null,"mechanism":"Alyftrek potentiates the CFTR protein to facilitate chloride ion flow into cells."},{"drug_id":"fusidic-acid","indication_name":"Synergy for P. Aeruginosa Infection in Cystic Fibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Myelofibrosis (MF) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"oligog-dry-powder-for-inhalation","indication_name":"Cystic Fibrosis (general)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"OligoG Dry powder for inhalation","company_name":"AlgiPharma AS","drug_phase":"discontinued","molecular_target":"Bacterial biofilm matrix and adhesion mechanisms in cystic fibrosis airways","drug_class":"Anti-biofilm agent; inhaled oligosaccharide therapeutic","quality_score":null,"revenue":null,"mechanism":"OligoG is an inhaled oligosaccharide that disrupts bacterial biofilm formation and reduces pathogenic adherence in cystic fibrosis airways."},{"drug_id":"oligog-dry-powder-for-inhalation","indication_name":"Cystic Fibrosis with Burkholderia spp. Infection","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"OligoG Dry powder for inhalation","company_name":"AlgiPharma AS","drug_phase":"discontinued","molecular_target":"Bacterial biofilm matrix and adhesion mechanisms in cystic fibrosis airways","drug_class":"Anti-biofilm agent; inhaled oligosaccharide therapeutic","quality_score":null,"revenue":null,"mechanism":"OligoG is an inhaled oligosaccharide that disrupts bacterial biofilm formation and reduces pathogenic adherence in cystic fibrosis airways."},{"drug_id":"oligog-dry-powder-for-inhalation","indication_name":"Lung Deposition Characterization in Cystic Fibrosis","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"OligoG Dry powder for inhalation","company_name":"AlgiPharma AS","drug_phase":"discontinued","molecular_target":"Bacterial biofilm matrix and adhesion mechanisms in cystic fibrosis airways","drug_class":"Anti-biofilm agent; inhaled oligosaccharide therapeutic","quality_score":null,"revenue":null,"mechanism":"OligoG is an inhaled oligosaccharide that disrupts bacterial biofilm formation and reduces pathogenic adherence in cystic fibrosis airways."},{"drug_id":"pf-05221304","indication_name":"NASH with fibrosis","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-05221304","generic_name":"pf-05221304","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Acetyl-CoA carboxylase (ACC1 and ACC2)","drug_class":"Acetyl-CoA carboxylase inhibitor","quality_score":27,"revenue":null,"mechanism":"Selective inhibitor of acetyl-CoA carboxylase (ACC1/ACC2) that reduces hepatic lipogenesis and promotes fatty acid oxidation."}],"offLabel":[],"totalMarketed":58,"totalPipeline":4},"trials":{"data":[{"nct_id":"NCT05253859","title":"CFTR Modulators and Gastrointestinal Complications","phase":"","overall_status":"COMPLETED","enrollment_count":47023,"lead_sponsor_name":"Nottingham University Hospitals NHS Trust","has_results":false},{"nct_id":"NCT03840928","title":"PatientSpot Formerly Known as ArthritisPower","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Global Healthy Living Foundation","has_results":false},{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT06868394","title":"Chronic Liver Disease and Radiation-induced Second Primary Liver Malignancy","phase":"","overall_status":"COMPLETED","enrollment_count":20846,"lead_sponsor_name":"Suez Canal University","has_results":false},{"nct_id":"NCT06248580","title":"Find HDV and Determine Its Status in Turkey","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Yaşar Bayındır, MD","has_results":false},{"nct_id":"NCT03958071","title":"A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking","phase":"","overall_status":"COMPLETED","enrollment_count":13264,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT06485635","title":"Real-life-persistence to Antifibrotic Treatments","phase":"","overall_status":"COMPLETED","enrollment_count":10646,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT02607722","title":"All-Case Surveillance of Ofev in Patients With IPF in Japan","phase":"","overall_status":"COMPLETED","enrollment_count":10117,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT04442334","title":"The European NAFLD Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Newcastle University","has_results":false},{"nct_id":"NCT05382572","title":"Pulmonary Fibrosis Foundation Community Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Pulmonary Fibrosis Foundation","has_results":false},{"nct_id":"NCT05681962","title":"Practice of Oxygenation and Respiratory Support During Fiberoptic Bronchoscopy","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"University Magna Graecia","has_results":false},{"nct_id":"NCT06528418","title":"Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"ChromX Health","has_results":false},{"nct_id":"NCT05651724","title":"Global Research Initiative for Patients Screening on MASH","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Julius Clinical","has_results":false},{"nct_id":"NCT05974904","title":"Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study","phase":"","overall_status":"RECRUITING","enrollment_count":7000,"lead_sponsor_name":"Chongqing Medical University","has_results":false},{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT03308916","title":"Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers","phase":"NA","overall_status":"RECRUITING","enrollment_count":6500,"lead_sponsor_name":"Maja Thiele","has_results":false},{"nct_id":"NCT04444128","title":"IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General populatION","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Johann Wolfgang Goethe University Hospital","has_results":false},{"nct_id":"NCT07362225","title":"MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"MPN Research Foundation","has_results":false},{"nct_id":"NCT03350828","title":"CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Nicole Hamblett","has_results":false},{"nct_id":"NCT06599892","title":"CF Organization of Care in the Era of Highly Effective Modulator.","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT00001532","title":"Role of Genetic Factors in the Development of Lung Disease","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT04487938","title":"Oral Cancer Screening and Education in Hong Kong","phase":"","overall_status":"UNKNOWN","enrollment_count":3190,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT03884062","title":"Clinical Impacts of Achieving SVR in Patients With Advanced Hepatic Fibrosis Related to Chronic HCV Treated With Direct Acting Antivirals","phase":"","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"Egyptian Liver Hospital","has_results":false},{"nct_id":"NCT05075785","title":"Covid-19 Respiratory Sequelae French Cohort","phase":"","overall_status":"COMPLETED","enrollment_count":2933,"lead_sponsor_name":"Centre Hospitalier Universitaire, Amiens","has_results":false},{"nct_id":"NCT07178392","title":"Disease-syndrome Characteristics of IPF","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2864,"lead_sponsor_name":"Henan University of Traditional Chinese Medicine","has_results":false},{"nct_id":"NCT05779007","title":"Dose Reduction and Discontinuation With Anti-Fibrotic Medications","phase":"","overall_status":"COMPLETED","enrollment_count":2778,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT05301686","title":"Is There a Correlation Between Surgical Technique for Primary Anterior Cruciate Ligament Surgery and the Risk of Subsequent Formation of Fibrous Cyst (Cyclops) in the Knee Joint, Which Leads to the Need for Surgical Removal of the Cyclops?","phase":"","overall_status":"COMPLETED","enrollment_count":2556,"lead_sponsor_name":"Aarhus University Hospital","has_results":false},{"nct_id":"NCT04896138","title":"University of Virginia Natural History Study","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":2500,"lead_sponsor_name":"University of Virginia","has_results":false},{"nct_id":"NCT07441408","title":"Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":2277,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT01493414","title":"INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2233,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT01688011","title":"Connect® Myeloid Disease Registry","phase":"","overall_status":"TERMINATED","enrollment_count":2013,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT02758808","title":"Pulmonary Fibrosis Foundation Patient Registry","phase":"","overall_status":"COMPLETED","enrollment_count":2004,"lead_sponsor_name":"Pulmonary Fibrosis Foundation","has_results":false},{"nct_id":"NCT07038863","title":"Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT04930289","title":"Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":2000,"lead_sponsor_name":"Paragonix Technologies","has_results":false},{"nct_id":"NCT03052283","title":"Development and Validation of a Disease Specific PROM to Assess Abdominal Involvement in Patients With CF (CFAbd-Score)","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Medizinische Hochschule Brandenburg Theodor Fontane","has_results":false},{"nct_id":"NCT05663255","title":"Effectiveness of CFTR Modulators According to Co-therapy","phase":"","overall_status":"UNKNOWN","enrollment_count":1990,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT03745378","title":"Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)","phase":"","overall_status":"COMPLETED","enrollment_count":1881,"lead_sponsor_name":"FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS","has_results":false},{"nct_id":"NCT06632444","title":"LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1800,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT05022784","title":"Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients","phase":"","overall_status":"COMPLETED","enrollment_count":1798,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT05870956","title":"Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients","phase":"","overall_status":"COMPLETED","enrollment_count":1798,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT05699018","title":"Screening in Primary Care of Advanced Liver Fibrosis in NAFLD And/or Alcoholic Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":1788,"lead_sponsor_name":"University Hospital, Angers","has_results":false},{"nct_id":"NCT04594369","title":"A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1767,"lead_sponsor_name":"Insmed Incorporated","has_results":true},{"nct_id":"NCT07270822","title":"Screening for MASLD-related Advanced Fibrosis in Type 2 Diabetes","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1714,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT06238622","title":"A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1700,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT06106789","title":"A Study of the Clinical Benefit of Tobramycin Inhalation Solution","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"Qianfoshan Hospital","has_results":false},{"nct_id":"NCT03120481","title":"Controls for Respiratory Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":1572,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT05337163","title":"A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China","phase":"","overall_status":"COMPLETED","enrollment_count":1564,"lead_sponsor_name":"Creative Biosciences (Guangzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT06785870","title":"EVAluation of Erythrocytosis PRospEctive Cohort STudy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Cyrus Hsia","has_results":false},{"nct_id":"NCT06685874","title":"Interstitial Lung Disease Exacerbations Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Royal Devon and Exeter NHS Foundation Trust","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}